- Home
- BCAB vs ONCY Comparison
BCAB vs ONCY Comparison
Compare BCAB & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- ONCY
- Stock Information
- Founded
- BCAB 2007
- ONCY 1998
- Country
- BCAB United States
- ONCY Canada
- Employees
- BCAB N/A
- ONCY N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- ONCY Pharmaceuticals and Biotechnology
- Sector
- BCAB Health Care
- ONCY Health Care
- Exchange
- BCAB Nasdaq
- ONCY Nasdaq
- Market Cap
- BCAB 22.3M
- ONCY 49.1M
- IPO Year
- BCAB 2020
- ONCY 1999
- Fundamental
- Price
- BCAB $0.38
- ONCY $0.77
- Analyst Decision
- BCAB Buy
- ONCY Strong Buy
- Analyst Count
- BCAB 2
- ONCY 4
- Target Price
- BCAB $1.00
- ONCY $4.33
- AVG Volume (30 Days)
- BCAB 633.5K
- ONCY 1.2M
- Earning Date
- BCAB 08-07-2025
- ONCY 07-31-2025
- Dividend Yield
- BCAB N/A
- ONCY N/A
- EPS Growth
- BCAB N/A
- ONCY N/A
- EPS
- BCAB N/A
- ONCY N/A
- Revenue
- BCAB $11,000,000.00
- ONCY N/A
- Revenue This Year
- BCAB N/A
- ONCY N/A
- Revenue Next Year
- BCAB N/A
- ONCY N/A
- P/E Ratio
- BCAB N/A
- ONCY N/A
- Revenue Growth
- BCAB N/A
- ONCY N/A
- 52 Week Low
- BCAB $0.24
- ONCY $0.33
- 52 Week High
- BCAB $2.53
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- BCAB 43.16
- ONCY 70.82
- Support Level
- BCAB $0.36
- ONCY $0.56
- Resistance Level
- BCAB $0.43
- ONCY $0.77
- Average True Range (ATR)
- BCAB 0.05
- ONCY 0.09
- MACD
- BCAB -0.01
- ONCY 0.02
- Stochastic Oscillator
- BCAB 11.48
- ONCY 88.51
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.